ProCE Banner Activity

First-in-Human Phase I Study of AMG 701: Anti-BCMA Bispecific Antibody in Patients With R/R MM

Slideset Download

Initial results from this ongoing phase I study suggest that once-weekly administration of AMG 701 yields encouraging activity with the possibility for deep, durable responses, along with a manageable safety profile.

Released: December 07, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology